Quality of life in children requiring antithrombotic therapy: development of a measure.
Measurement of quality of life (QOL) has been accepted as an important outcome measure in therapeutic clinical trials. Long-term antithrombotic therapy is hypothesized to induce treatment dissatisfaction and influence QOL. Health-related quality of life (HRQOL) can be measured by an inventory developed specific to the patient condition. Pediatric QOL inventory for children on long-term antithrombotic therapy should assess constructs salient for this population. Creation of an HRQOL measurement inventory requires rigor and methodological adherence. Identification and evaluation of QOL constructs is critical to improve care and is accepted as the "gold standard" measurement for patient-centered outcomes in clinical research. The use of a valid and reliable HRQOL inventory specific for the antithrombotic therapy is required for upcoming clinical trials as it will provide a method to measure change in HRQOL specific to the antithrombotic agent. In this way, it will be possible to provide the child/family with information to make safe and effective therapeutic choices, define future antithrombotic therapy research strategies, and inform decision makers to change policies to improve health care.